You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TGR-1202

Showing 1 - 25 of 41
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Myelofibrosis, Polycythemia Vera Trial in United States (TGR-1202, ruxolitinib)

Active, not recruiting
  • Myelofibrosis
  • Polycythemia Vera
  • Phoenix, Arizona
  • +4 more
Jun 20, 2022

Follicular Lymphoma Trial in New York (TGR-1202)

Terminated
Has Results
  • Follicular Lymphoma
  • TGR-1202
  • New York, New York
    Columbia University Medical Center
Jun 28, 2021

Hodgkin Disease, Lymphoma, Non-hodgkin Trial in New York (Carfilzomib, TGR-1202)

Terminated
Has Results
  • Hodgkin Disease
  • Lymphoma, Non-hodgkin
  • New York, New York
    Columbia University Irving Medical Center - Center for Lymphoid
Jun 28, 2021

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +5 more
Sep 6, 2021

Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL Trial in New York (Umbralisib, Ublituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • New York, New York
    Weill Cornell Medicine
Mar 29, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Omaha (Ibrutinib, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202)

Completed
Has Results
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Omaha, Nebraska
    University of Nebraska Medical Center
Feb 12, 2020

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
Aug 19, 2022

Mantle Cell Lymphoma Trial in Birmingham (Ublituximab, Umbralisib)

Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 8, 2021

Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +2 more
Aug 19, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)

Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jul 31, 2022

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma Trial in United States (Ublituximab + TGR-1202, Ublituximab + TGR-1202 +

Completed
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
  • Ublituximab + TGR-1202
  • +2 more
  • Huntsville, Alabama
  • +5 more
Nov 4, 2019

Chronic Lymphocytic Leukemia Trial in Huntsville, Memphis (TGR-1202 + Obinutuzumab + Chlorambucil)

Completed
  • Chronic Lymphocytic Leukemia
  • TGR-1202 + Obinutuzumab + Chlorambucil
  • Huntsville, Alabama
  • +1 more
Oct 1, 2019

Hodgkin's Lymphoma Trial in United States (TGR-1202 + brentuximab vedotin)

Completed
  • Hodgkin's Lymphoma
  • TGR-1202 + brentuximab vedotin
  • Duarte, California
  • +3 more
Oct 1, 2019

Pancreatic Cancer, Colorectal Cancer, Rectal Cancer Trial in Nashville (TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin +

Completed
  • Pancreatic Cancer
  • +5 more
  • TGR-1202
  • +3 more
  • Nashville, Tennessee
    TG Therapeutics Trial Site
Oct 1, 2019

Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1 Trial in Boston (Umbralisib, Rituximab)

Recruiting
  • Lymphoma
  • +6 more
  • Boston, Massachusetts
  • +1 more
Aug 31, 2020

Chronic Lymphocytic Leukemia Trial in Worldwide (Obinutuzumab, Ublituximab, TGR-1202)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Obinutuzumab
  • +3 more
  • Huntsville, Alabama
  • +153 more
Aug 19, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Ublituximab, Umbralisib, Venetoclax)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Birmingham, Alabama
  • +49 more
Mar 22, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in United States (Bendamustine

Suspended
  • Grade 1 Follicular Lymphoma
  • +4 more
  • Bendamustine Hydrochloride
  • +7 more
  • Anchorage, Alaska
  • +422 more
Aug 24, 2022

Tumor Growth Rate Predicts Clinical Outcomes for Advanced

Recruiting
  • Non-Small Cell Lung Cancer
  • This item is not applicable to our observational study.
  • Guangzhou, Guangdong, China
  • +2 more
Mar 15, 2021

Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202 in combination with Epirubicin, Placebo in combination with

Active, not recruiting
  • Non-muscle Invasive Bladder Cancer
  • APL-1202 in combination with Epirubicin
  • Placebo in combination with Epirubicin
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 21, 2022

Muscle Invasive Bladder Cancer Trial in New York, Shanghai (APL-1202 in combination with tislelizumab, Tislelizumab alone)

Recruiting
  • Muscle Invasive Bladder Cancer
  • APL-1202 in combination with tislelizumab
  • Tislelizumab alone
  • New York, New York
  • +1 more
Feb 21, 2022

IPF Trial in Istanbul (Telerehabilitation exercise program, Videobased exercise program)

Recruiting
  • IPF
  • Telerehabilitation exercise program
  • Videobased exercise program
  • Istanbul, Zeytinburnu, Turkey
    Yedikule Chest Disease Hospital
Jan 22, 2022

Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202, Epirubicin Hydrochloride)

Recruiting
  • Non-muscle Invasive Bladder Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 21, 2022